Cryolife, Inc. to Open European Headquarters.

ATLANTA--(BW HealthWire)--Aug. 16, 1999--

CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced plans to set up a European headquarters operation near London, England. The new facility will provide distribution and technical services to CryoLife's network of European representatives, insgrowth rate of approximately 50% in European rev base in 1996 with the introduction of the CryoLife-O'Brien(R) stentless porcine heat valve, which addresses an estimated $75 million USD European tissue heart valve mare and porcine heart valves were $900,000 USD in the first six months of 1999.

In the United States, BioGlue is undergoing Food and Drug Administration (FDA) approved human clinical trials for use in the repair of aortic dissections.will report directly to the President and Chief valve replacement device. It is anticipated that SynerGraft European human trials will start later this year.

Dr. Hanley has extensive experience in medical deviceent and marketing of phosphorylcholine-containito be associated with a series of new tissue devices and surgical adhesives that have the potential to introrcialization of living human tissue implantable ty.

Editor's Note: CryoLife Customer Serviceinformation about the Company, visit CryoLife's web site: http://www.cryolife.com